Jesse Schulman

Cooley advised TPB Acquisition Corporation I, a special purpose acquisition company sponsored by The Production Board, in its business combination agreement that will result in Lavoro Limited, a leading agricultural inputs retailer in Latin America, becoming a US publicly listed company with an implied initial enterprise value of approximately $1.2 billion.

Cooley advised the underwriters in LumiraDx Limited’s $100.3 million aggregate financing, consisting of (1) a $75.3 million follow-on offering of 43,000,000 shares of common stock at a public offering price of $1.75 per share and (2) a $25.0 million concurrent private placement with the Bill & Melinda Gates Foundation. LumiraDx is a diagnostics company manufacturing and commercializing an innovative diagnostic platform that supports a broad menu of tests with lab-comparable performance at the point of care. Partners Denny Won, Kristin VanderPas, Charlie Kim and Dave Peinsipp led the Cooley team.

Cooley advised Truebill, a personal finance app that helps consumers manage their financial lives, on its agreement to sell to tech-driven real estate, mortgage and financial services business platform Rocket Companies for $1.275 billion. Kevin Cooper led the Cooley team advising Truebill on this transaction, and Mike Lincoln at Cooley has worked with the company since its inception.

Cooley advised the underwriters on Biomea Fusion’s $153 million initial public offering of 9,000,000 shares of common stock. J.P. Morgan Securities, Jefferies and Piper Sandler acted as joint book-running managers for the offering. Biomea Fusion, whose securities now trade on the Nasdaq Global Select Market under the symbol BMEA, is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Partners Charlie Kim, Jonie Kondracki and Kristin VanderPas led the Cooley team.

Cooley advised Archer, a leader in the urban air mobility space, on its agreement to combine with special purpose acquisition company Atlas Crest Investment. Estimated to have an implied $3.8 billion pro forma equity value, the combined company will list on the New York Stock Exchange under the symbol “ACHR.” Partners Dave Peinsipp, John McKenna and Al Browne led the Cooley team advising Archer on the transaction, which is expected to close in Q2.